RegulatoryJun 24, 2026, 04:16 PM
Apollomics Receives Nasdaq Delisting Notice for MVLS Non-Compliance
AI Summary
Apollomics Inc. announced it received a notice from Nasdaq for non-compliance with the minimum Market Value of Listed Securities (MVLS) requirement of $35 million. The company's MVLS fell below this threshold for 30 consecutive business days, and it has 180 calendar days, until December 15, 2026, to regain compliance. Separately, Apollomics terminated its collaboration agreement with Launxp International Co., Ltd. due to Launxp's failure to pay a $3.8 million balance, resulting in Apollomics regaining all rights to its lead asset, vebreltinib (APL-101), in Asia, and now holding all global rights outside Mainland China and Macau.
Key Highlights
- Apollomics received a Nasdaq notice for not maintaining a minimum Market Value of Listed Securities (MVLS) of $35 million.
- The MVLS was below $35 million for 30 consecutive business days from May 6 to June 17, 2026.
- The company has a 180-calendar-day compliance period to regain compliance, expiring December 15, 2026.
- Compliance requires MVLS to close at or above $35 million for a minimum of 10 consecutive business days.
- Apollomics terminated its Collaboration and License Agreement with Launxp International Co., Ltd. due to failure to remit a $3.8 million payment.
- Apollomics has regained all previously licensed rights to vebreltinib (APL-101) in Asia.
- Apollomics now holds all global rights to vebreltinib outside of Mainland China and Macau.
Price Impact
More from APLM